Your browser doesn't support javascript.
loading
A phase II study of MK-2206, an AKT inhibitor, in uterine serous carcinoma.
Stover, Elizabeth H; Xiong, Niya; Myers, Andrea P; Tayob, Nabihah; Engvold, Victoria; Polak, Madeline; Broaddus, Russell R; Makker, Vicky; Drapkin, Ronny; Liu, Joyce F; Horowitz, Neil S; Meric-Bernstam, Funda; Aghajanian, Carol; Coleman, Robert L; Mills, Gordon B; Cantley, Lewis C; Matulonis, Ursula A; Westin, Shannon N; Konstantinopoulos, Panagiotis A.
Afiliación
  • Stover EH; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States.
  • Xiong N; Department of Data Science, Dana-Farber Cancer Institute, Boston, MA, United States.
  • Myers AP; Novartis, East Hanover, NJ, United States.
  • Tayob N; Department of Data Science, Dana-Farber Cancer Institute, Boston, MA, United States.
  • Engvold V; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States.
  • Polak M; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States.
  • Broaddus RR; Department of Pathology, University of Texas M. D. Anderson Cancer Center, Houston, TX, United States.
  • Makker V; Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, United States.
  • Drapkin R; Penn Ovarian Cancer Research Center, Department of Obstetrics and Gynecology, Basser Center for BRCA, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, United States.
  • Liu JF; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States.
  • Horowitz NS; Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Dana Farber Cancer Institute, Boston, MA, United States.
  • Meric-Bernstam F; Department of Investigational Cancer Therapeutics, University of Texas M. D. Anderson Cancer Center, Houston, TX, United States.
  • Aghajanian C; Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, United States.
  • Coleman RL; Department of Gynecologic Oncology and Reproductive Medicine, University of Texas M. D. Anderson Cancer Center, Houston, TX, United States.
  • Mills GB; Division of Oncologic Sciences, Knight Cancer Institute, Oregon Health and Science University, United States.
  • Cantley LC; Department of Medicine, Weill Cornell Medical College, New York, NY, United States.
  • Matulonis UA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States.
  • Westin SN; Department of Gynecologic Oncology and Reproductive Medicine, University of Texas M. D. Anderson Cancer Center, Houston, TX, United States.
  • Konstantinopoulos PA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States.
Gynecol Oncol Rep ; 40: 100974, 2022 Apr.
Article en En | MEDLINE | ID: mdl-35434236
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: Gynecol Oncol Rep Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: Gynecol Oncol Rep Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos